Marken Launches Solo For Management of Clinical Trials Distribution
Marken announced the launch of Solo™, their proprietary web based system used to manage the regulatory, inventory, and operational supply chain complexities of clinical trials. The system, which has been developed exclusively for Marken, is designed to manage all aspects of Marken’s global depot network including: receipt of clinical supplies and kits, dispatches, returns, warehouse movements, and QA releases. Solo™ is a secure, validated*, web-based system which is fully accessible to Marken’s clients on a 24/7 basis from any location in the world. Additionally, Marken has designed Solo™ to integrate with multiple client-directed IXR (Interactive Reporting) systems.
“We are pleased to offer this new system to our growing number of pharmaceutical clients”, said Frank Wright, Interim President, Clinical Trials Distribution at Marken.
“Solo is fit for purpose application which incorporates all of our client’s requirements for remote storage and distribution of their clinical trial supplies. We are also excited to be launching Solo as we manage an increasing number of depots around the world”. Solo™ is purpose-built to allow a high degree of customization supporting the dynamic needs of Marken’s pharmaceutical client base. The system is being launched just as Marken is opening its third fully owned and staffed depot facility in Buenos Aires, Argentina.
*validated in accordance with 21 CFR part 11
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
